Heparanase as a target in cancer therapy

Current Cancer Drug Targets

Volumn 14, Issue 3, 2014, Pages 286-293

  Masola, Valentina ^a   Secchi, Maria Francesca ^a   Gambaro, Giovanni ^b   Onisto, Maurizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Angiogenesis; Cancer; Extracellular matrix; Heparan sulfate; Heparanase; Heparanase inhibitors; Metastasis

Indexed keywords

AGRIN; CYTOKINE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PEROXIDASE; GELATINASE A; GEMCITABINE; GROWTH FACTOR; HEPARAN SULFATE; HEPARANASE; LOW MOLECULAR WEIGHT HEPARIN; MAJOR BASIC PROTEIN; MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN; PERLECAN; PROTEIN KINASE B; PROTEIN P53; SYNAPTOPHYSIN; SYNDECAN 1; UROKINASE; VASCULOTROPIN A; BETA GLUCURONIDASE;

ANGIOGENESIS; CANCER GROWTH; CANCER THERAPY; CAPILLARY DENSITY; CELL ADHESION; CELL SURVIVAL; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; HPSE 1 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METASTASIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; VASCULARIZATION; WOUND HEALING; DISEASE COURSE; NEOPLASMS; PATHOLOGY;

DISEASE PROGRESSION; GLUCURONIDASE; HUMANS; NEOPLASMS;

EID: 84903743787     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140224155124     Document Type: Review

References (102)

1. Valastyan S.; Weinberg R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147, 275-292.
2. Ilan N.; Elkin M.; Vlodavsky I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell. Biol. 2006, 38(12), 2018-2039.
3. McKenzie E. A. Heparanase: a target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 2007, 151(1), 1-14.
4. Meirovitz A.; Goldberg R.; Binder A.; Rubinstein A. M.; Hermano E.; Elkin M. Heparanase in inflammation and inflammationassociated cancer. FEBS J. 2013, 280(10), 2307-2319.
5. Ramani V. C.; Purushothaman A.; Stewart M. D.; Thompson C. A.; Vlodavsky I.; Au J. L.; Sanderson R. D. The heparanase/syndecan- 1 axis in cancer: mechanisms and therapies. FEBS J. 2013, 280(10), 2294-2306.
6. Vlodavsky I.; Ilan N.; Naggi A.; Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 2007, 13(20), 2057-2073.
7. Dong J.; Kukula A. K.; Toyoshima M.; Nakajima M. Genomic organization and chromosome localization of the newly identified human heparanase gene. Gene 2000, 253(2), 171-178.
8. Vreys V.; Delande N.; Zhang Z.; Coomans C.; Roebroek A.; Durr J.; David G. Cellular uptake of mammalian heparanase prevursor involves low density lipoprotein receptor- related proteins, mannose 6-phosphate receptors, and heparan sulfate proteoglycans. J. Biol. Chem. 2005, 280(39), 33141-33148.
9. Abboud-Jarrous G.; Atzmon R.; Peretz T.; Palermo C.; Gadea B. B.; Joyce J. A.;Vlodavsky I. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J. Biol. Chem. 2008, 283(26), 18167-18176.
10. Fairbanks M. B.; Mildner A. M.; Leone J. W.; Cavey G. S.; Mathews W. R.; Drong R. F.; Slightom J. L.; Bienkowski M. J.; Smith C. W.; Bannow C. A.; Heinrikson R. L. Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer. J. Biol. Chem. 1999, 274(42), 29587-29590.
11. Nadav L.; Eldor A.; Yacoby-Zeevi O.; Zamir E.; Pecker I.; Ilan N.; Geiger B.; Vlodavsky I.; Katz B. Z. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J. Cell. Sci. 2002, 115(Pt 10), 2179-2187.
12. Fuller M.; Chau A.; Nowak R. C.; Hopwood J. J.; Meikle P. J. A defect in exodegradative pathways provides insight into endodegradation of heparan and dermatan sulfates. Glycobiology 2006, 16(4), 318-325.
13. Nobuhisa T.; Naomoto Y.; Okawa T.; Takaoka M.; Gunduz M.; Motoki T.; Nagatsuka H.; Tsujigiwa H.; Shirakawa Y.; Yamatsuji T.; Haisa M.; Matsuoka J.; Kurebayashi J.; Nakajima M.; Taniguchi S.; Sagara J.; Dong J.; Tanaka N. Translocation of heparanase into nucleus results in cell differentiation. Cancer Sci. 2007, 98(4), 535-540.
14. Chen L.; Sanderson R. D. Heparanase regulates levels of syndecan- 1 in the nucleus. PLoS One 2009, 4(3), e4947.
15. Fux L.; Ilan N.; Sanderson R. D.; Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem. Sci. 2009, 34(10), 511-519.
16. Fux L.; Feibish N.; Cohen-Kaplan V.; Gingis-Velitski S.; Feld S.; Geffen C.; Vlodavsky I.; Ilan N. Structure-function approach identifies a COOH-terminal domain that mediates heparanase signaling. Cancer Res. 2009, 69(5), 1758-1767.
17. Haimov-Kochman R.; Friedmann Y.; Prus D.; Goldman-Wohl D. S.; Greenfield C.; Anteby E. Y.; Aviv A.; Vlodavsky I.; Yagel S. Localization of heparanase in normal and pathological human placenta. Mol. Hum. Reprod. 2002, 8(6), 566-573.
18. Vlodavsky I.; Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108(3), 341-347.
19. Dempsey L. A.; Plummer T. B.; Coombes S. L.; Platt J. L. Heparanase expression in invasive trophoblasts and acute vascular damage. Glycobiology 2000, 10(5), 467-475.
20. Goldshmidt O.; Zcharia E.; Aingorn H.; Guatta-Rangini Z.; Atzmon R.; Michal I.; Pecker I.; Mitrani E.; Vlodavsky I. Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence. J. Biol. Chem. 2001, 276(31), 29178-29187.
21. Zcharia E.; Philp D.; Edovitsky E.; Aingorn H.; Metzger S.; Kleinman H. K.; Vlodavsky I.; Elkin M. Heparanase regulates murine hair growth. Am. J. Pathol. 2005, 166(4), 999-1008.
22. Zcharia E.; Zilka R.; Yaar A.; Yacoby-Zeevi O.; Zetser A.; Metzger S.; Sarid R.; Naggi A.; Casu B.; Ilan N.; Vlodavsky I.; Abramovitch R. Heparanase accelerates wound angiogenesis and wound healing in mouse and rat models. FASEB J. 2005, 19(2), 211-221.
23. Friedmann Y.; Vlodavsky I.; Aingorn H.; Aviv A.; Peretz T.; Pecker I.; Pappo O. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am. J. Pathol. 2000, 157(4), 1167-1175.
24. Gohji K.; Okamoto M.; Kitazawa S.; Toyoshima M.; Dong J.; Katsuoka Y.; Nakajima M. Heparanase protein and gene expression in bladder cancer. J. Urol. 2001, 166(4), 1286-1290.
25. Koliopanos A.; Friess H.; Kleeff J.; Shi X.; Liao Q.; Pecker I.; Vlodavsky I.; Zimmermann A.; Büchler M. W. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res. 2001, 61(12), 4655-4659.
26. Shinyo Y.; Kodama J.; Hongo A.; Yoshinouchi M.; Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann. Oncol. 2003, 14(10), 1505-1510.
27. Zeng C.; Ke Z. F.; Luo W. R.; Yao Y. H.; Hu X. R.; Jie W.; Yin J. B.; Sun S. J. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo. Med. Oncol. 2013, 30(1), 403.
28. Marchetti D.; Nicolson G. L. Human heparanase: a molecular determinant of brain metastasis. Adv. Enzyme Regul. 2001, 41, 343-59.
29. Ogishima T.; Shiina H.; Breault J. E.; Tabatabai L.; Bassett W. W.; Enokida H.; Li L. C.; Kawakami T.; Urakami S.; Ribeiro-Filho L. A.; Terashima M.; Fujime M.; Igawa M.; Dahiya R. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res. 2005, 11(3), 1028-1036.
30. Xu X.; Quiros R. M.; Maxhimer J. B.; Jiang P.; Marcinek R.; Ain K. B.; Platt J. L.; Shen J.; Gattuso P.; Prinz R. A. Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis. Clin Cancer Res. 2003, 9(16 Pt 1), 5968-5979.
31. El-Assal O. N.; Yamanoi A.; Ono T.; Kohno H.; Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 2001, 7(5), 1299-1305.
32. Bitan M.; Polliack A.; Zecchina G.; Nagler A.; Friedmann Y.; Nadav L.; Deutsch V.; Pecker I.; Eldor A.; Vlodavsky I.; Katz B. Z. Heparanase expression in human leukemias is restricted to acute myeloid leukemias. Exp. Hematol. 2002, 30(1), 34-41.
33. Takaoka M.; Naomoto Y.; Ohkawa T.; Uetsuka H.; Shirakawa Y.; Uno F.; Fujiwara T.; Gunduz M.; Nagatsuka H.; Nakajima M.; Tanaka N.; Haisa M. Heparanase expression correlates with invasion and poor prognosis in gastric cancers. Lab. Invest. 2003, 83(5), 613-622.
34. Watanabe M.; Aoki Y.; Kase H.; Tanaka K. Heparanase expression and angiogenesis in endometrial cancer. Gynecol. Obstet. Invest. 2003, 56(2), 77-82.
35. Hasengaowa Kodama J., Kusumoto T.; Seki N.; Matsuo T.; Ojima Y.; Nakamura K.; Hongo A.; Hiramatsu Y. Heparanase expression in both normal endometrium and endometrial cancer. Int. J. Gynecol. Cancer 2006, 16(3), 1401-1406.
36. Yang Y.; Macleod V.; Bendre M.; Huang Y.; Theus A. M.; Miao H. Q.; Kussie P.; Yaccoby S.; Epstein J.; Suva L. J.; Kelly T.; Sanderson R. D. Heparanase promotes the spontaneous metastasis of myeloma cells to bone. Blood 2005, 105(3), 1303-1309.
37. Davidson B.; Shafat I.; Risberg B.; Ilan N.; Trope' CG.; Vlodavsky I.; Reich R. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol. Oncol. 2007, 104(2), 311-319.
38. Masola V.; Maran C.; Tassone E.; Zin A.; Rosolen A.; Onisto M. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer. 2009, 9, 304.
39. Shafat I.; Barak A. B.; Postovsky S.; Elhasid R.; Ilan N.; Vlodavsky I.; Arush M. W. Heparanase levels are elevated in the plasma of pediatric cancer patients and correlate with response to anticancer treatment. Neoplasia 2007, 9(11), 909-916.
40. Ben Arush M. W.; Shafat I.; Ben Barak A.; Shalom R. B.; Vlodavsky I.; Ilan N. Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study. Pediatr. Hematol. Oncol. 2009, 26(4), 157-164.
41. Sato T.; Yamaguchi A.; Goi T.; Hirono Y.; Takeuchi K.; Katayama K.; Matsukawa S. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J. Surg. Oncol. 2004, 87(4), 174-181.
42. Baraz L.; Haupt Y.; Elkin M.; Peretz T.; Vlodavsky I. Tumor suppressor p53 regulates heparanase gene expression. Oncogene 2006, 25(28), 3939-3947.
43. Shteper P. J.; Zcharia E.; Ashhab Y.; Peretz T.; Vlodavsky I.; Ben-Yehuda D. Role of promoter methylation in regulation of the mammalian heparanase gene. Oncogene 2003, 22(49), 7737-7749.
44. Ogishima, T.; Shiina, H.; Breault, J.E.; Terashima, M.; Honda, S.; Enokida, H.; Urakami, S.; Tokizane, T.; Kawakami, T.; Ribeiro- Filho, L.A.; Fujime, M.; Kane, C.J.; Carroll, P.R.; Igawa, M.; Dahiya, R. Promoter CpG hypomethylation and transcription factor EGR1 hyperactivate heparanase expression in bladder cancer. Oncogene 2005, 24(45), 6765-6772.
45. Elkin M.; Cohen I.; Zcharia E.; Orgel A.; Guatta-Rangini Z.; Peretz T.; Vlodavsky I.; Kleinman H. K. Regulation of heparanase gene expression by estrogen in breast cancer. Cancer Res. 2003, 63(24), 8821-8826.
46. Li J. P.; Vlodavsky I. Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb. Haemost. 2009, 102(5), 823-828.
47. Waterman M.; Ben-Izhak O.; Eliakim R.; Groisman G.; Vlodavsky I.; Ilan N. Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod. Pathol. 2007, 20(1), 8-14.
48. Vlodavsky I.; Eldor A.; Haimovitz-Friedman A.; Matzner Y.; Ishai- Michaeli R.; Lider O.; Naparstek Y.; Cohen I. R.; Fuks Z. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis 1992, 12(2), 112-127.
49. Mantovani A.; Allavena P.; Sica A.; Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203), 436-444.
50. Lerner I.; Hermano E.; Zcharia E.; Rodkin D.; Bulvik R.; Doviner V.; Rubinstein A. M.; Ishai-Michaeli R.; Atzmon R.; Sherman Y.; Meirovitz A.; Peretz T.; Vlodavsky I.; Elkin M. Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J. Clin. Invest. 2011, 121(5), 1709-1721.
51. Stetler-Stevenson W. G.; Aznavoorian S.; Liotta L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell. Biol. 1993, 9, 541-573.
52. Nakajima M.; Irimura T.; Di Ferrante D.; Di Ferrante N.; Nicolson G. L. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science 1983, 220(4597), 611-613.
53. Vlodavsky I.; Fuks Z.; Bar-Ner M.; Ariav Y.; Schirrmacher V. Lymphoma cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relationship to tumor cell metastasis. Cancer Res. 1983, 43(6), 2704-2711.
54. Vlodavsky I.; Friedmann Y.; Elkin M.; Aingorn H.; Atzmon R.; Ishai-Michaeli R.; Bitan M.; Pappo O.; Peretz T.; Michal I.; Spector L.; Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999, 5(7), 793-802.
55. Uno F.; Fujiwara T.; Takata Y.; Ohtani S.; Katsuda K.; Takaoka M.; Ohkawa T.; Naomoto Y.; Nakajima M.; Tanaka N. Antisensemediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res. 2001, 61(21), 7855-7860.
56. Edovitsky E.; Elkin M.; Zcharia E.; Peretz T.; Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J. Natl. Cancer Inst. 2004, 96(16), 1219-1230.
57. Doweck I.; Kaplan-Cohen V.; Naroditsky I.; Sabo E.; Ilan N.; Vlodavsky I. Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival. Neoplasia 2006, 8(12), 1055-1061.
58. Nagler R.; Ben-Izhak O.; Cohen-Kaplan V.; Shafat I.; Vlodavsky I.; Akrish S.; Ilan N. Heparanase up-regulation in tongue cancer: tissue and saliva analysis. Cancer 2007, 110(12), 2732-2739.
59. El-Assal O. N.; Yamanoi A.; Ono T.; Kohno H.; Nagasue N. The clinicopathological significance of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. Clin. Cancer Res. 2001, 7(5), 1299-1305.
60. Maxhimer J.B.; Quiros R. M.; Stewart R.; Dowlatshahi K.; Gattuso P.; Fan M.; Prinz R. A.; Xu X. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery 2002, 132(2), 326-333.
61. Beckhove P.; Helmke B. M.; Ziouta Y.; Bucur M.; Dörner W.; Mogler C.; Dyckhoff G.; Herold-Mende C. Heparanase expression at the invasion front of human head and neck cancers and correlation with poor prognosis. Clin. Cancer Res. 2005, 11(8), 2899-2906.
62. Leiser Y.; Abu-El-Naaj I.; Sabo E.; Akrish S., Ilan N.; Ben-Izhak O.; Peled M.; Vlodavsky I. Prognostic value of heparanase expression and cellular localization in oral cancer. Head Neck 2011, 33(6), 871-877.
63. Ben-Izhak O.; Kaplan-Cohen V.; Ilan N.; Gan S.; Vlodavsky I.; Nagler R. Heparanase expression in malignant salivary gland tumors inversely correlates with long-term survival. Neoplasia 2006, 8(10), 879-884.
64. Elkin M.; Ilan N.; Ishai-Michaeli R.; Friedmann Y.; Papo O.; Pecker I.; Vlodavsky I. Heparanase as mediator of angiogenesis: mode of action. FASEB J. 2001, 15(9), 1661-1663.
65. Zcharia E.; Jian J.; Zhang X.; Baraz L.; Lindahl U.; Peretz T.; Vlodavsky I.; Li J. P. Newly generated heparanase knock-out mice unravel co-regulation of heparanase and matrix metalloproteinases. PLoS One 2009, 4(4), e5181.
66. Levy-Adam F.; Feld S.; Suss-Toby E.; Vlodavsky I.; Ilan N. Heparanase facilitates cell adhesion and spreading by clustering of cell surface heparan sulfate proteoglycans PLoS One 2008, 3(6), e2319.
67. Mahtouk K.; Hose D.; Raynaud P.; Hundemer M.; Jourdan M.; Jourdan E.; Pantesco V.; Baudard M.; De Vos J.; Larroque M.; Moehler T.; Rossi J. F.; Rème T.; Goldschmidt H.; Klein B. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood 2007, 109(11), 4914-4923.
68. Seidel C.; Sundan A.; Hjorth M.; Turesson I.; Dahl I. M.; Abildgaard N.; Waage A.; Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 2000, 95(2), 388-392.
69. Sanderson R. D.; Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis. 2008, 25(2), 149-59.
70. Yang Y.; Macleod V.; Miao H. Q.; Theus A.; Zhan F.; Shaughnessy J. D. Jr; Sawyer J.; Li J. P.; Zcharia E.; Vlodavsky I.; Sanderson R. D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282(18), 13326-13333.
71. Purushothaman A.; Chen L., Yang Y., Sanderson R. D. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J. Biol. Chem. 2008, 283(47), 32628-32636.
72. Goldshmidt O.; Zcharia E.; Cohen M.; Aingorn H.; Cohen I.; Nadav L.; Katz B. Z.; Geiger B.; Vlodavsky I. Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J. 2003, 17(9), 1015-1025.
73. Gingis-Velitski S.; Zetser A.; Flugelman M. Y.; Vlodavsky I.; Ilan N. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J. Biol. Chem. 2004, 279(22), 23536-23541.
74. Zetser A.; Bashenko Y.; Edovitsky E.; Levy-Adam F.; Vlodavsky I.; Ilan N. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res. 2006, 66(3), 1455-1463.
75. Cohen-Kaplan V.; Naroditsky I.; Zetser A.; Ilan N.; Vlodavsky I.; Doweck I. Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int. J. Cancer 2008 123(11), 2566-2573.
76. Cohen-Kaplan V.; Doweck I.; Naroditsky I.; Vlodavsky I., Ilan N. Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression. Cancer Res. 2008, 68(24), 10077-10085.
77. Masola V.; Gambaro G.; Tibaldi E.; Brunati A. M.; Gastaldello A.; D'Angelo A.; Onisto M.; Lupo A. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelialmesenchymal transition in renal tubular cells. J. Biol. Chem. 2012, 287(2), 1478-1488.
78. Thiery J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2(6), 442-454.
79. Scheel C.; Weinberg R. A. Cancer stem cells and epithelialmesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 2012, 22(5-6), 396-403.
80. Yang J.; Weinberg R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell. 2008, 14(6), 818-829.
81. Miao H. Q.; Liu H.; Navarro E.; Kussie P.; Zhu Z. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 2006, 13(18), 2101-2111.
82. Ferro V. Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses. Expert Opin. Ther. Targets. 2013, 17(8), 965-975.
83. Temkin V.; Aingorn H.; Puxeddu I.; Goldshmidt O.; Zcharia E.; Gleich G. J.; Vlodavsky I.; Levi-Schaffer F. Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J. Allergy Clin. Immunol. 2004, 113(4), 703-709.
84. Freeman C.; Parish C. R. Human platelet heparanase: purification, characterization and catalytic activity. Biochem. J. 1998, 330 (Pt 3), 1341-1350.
85. Naggi A.; Casu B.; Perez M.; Torri G.; Cassinelli G.; Penco S.; Pisano C.; Giannini G.; Ishai-Michaeli R.; Vlodavsky I. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J. Biol. Chem. 2005, 280(13), 12103-12113.
86. Lazo-Langner A.; Goss G. D.; Spaans J. N.; Rodger M. A. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J. Thromb. Haemost. 2007, 5(4), 729-737.
87. Parish C. R.; Freeman C.; Brown K. J.; Francis D. J.; Cowden W. B. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999, 59(14), 3433-3441.
88. Lewis K. D.; Robinson W. A.; Millward M. J.; Powell A.; Price T. J.; Thomson D. B.; Walpole E. T.; Haydon A. M.; Creese B. R.; Roberts K. L.; Zalcberg J. R.; Gonzalez R. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest. New Drugs 2008, 26(1), 89-94.
89. Dredge K.; Hammond E.; Davis K.; Li C. P.; Liu L.; Johnstone K.; Handley P.; Wimmer N.; Gonda T. J.; Gautam A.; Ferro V.; Bytheway I. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest. New Drugs 2010, 28(3), 276-283.
90. Ferro V.; Liu L.; Johnstone K. D.; Wimmer N.; Karoli T.; Handley P.; Rowley J.; Dredge K.; Li C. P.; Hammond E.; Davis K.; Sarimaa L.; Harenberg J.; Bytheway I. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J. Med. Chem. 2012, 55(8), 3804-3813.
91. Hammond E.; Handley P.; Dredge K.; Bytheway I. Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analogues. FEBS Open Bio. 2013, 3, 346-351.
92. Dredge K.; Hammond E.; Handley P.; Gonda T. J.; Smith M. T.; Vincent C.; Brandt R.; Ferro V.; Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br. J. Cancer 2011, 104(4), 635-642.
93. Hammond E.; Brandt R.; Dredge K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS One 2012, 7(12), e52175.
94. Zhou H.; Roy S.; Cochran E.; Zouaoui R.; Chu C. L.; Duffner J.; Zhao G.; Smith S.; Galcheva-Gargova Z.; Karlgren J.; Dussault N.; Kwan R. Y.; Moy E.; Barnes M.; Long A.; Honan C.; Qi Y. W.; Shriver Z.; Ganguly T.; Schultes B.; Venkataraman G.; Kishimoto T.K402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis. PLoS One 2011, 6(6), e21106.
95. Ritchie J. P.; Ramani V. C.; Ren Y.; Naggi A.; Torri G.; Casu B.; Penco S.; Pisano C.; Carminati P.; Tortoreto M.; Zunino F.; Vlodavsky I.; Sanderson R. D.; Yang Y. SST0001, chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin. Cancer Res. 2011, 17(6), 1382-1393.
96. Cassinelli G.; Lanzi C.; Tortoreto M.; Cominetti D.; Petrangolini G.; Favini E.; Zaffaroni N.; Pisano C.; Penco S.; Vlodavsky I.; Zunino F. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem. Pharmacol. 2013, 85(10), 1424-1432.
97. Courtney S. M.; Hay P. A.; Buck R. T.; Colville C. S.; Porter D. W.; Scopes D. I.; Pollard F. C.; Page M. J.; Bennett J. M.; Hircock M. L., McKenzie E. A.; Stubberfield C. R.; Turner P. R. 2, 3- Dihydro-1, 3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14(12), 3269-3273.
98. Courtney S. M.; Hay P. A.; Buck R. T.; Colville C. S.; Phillips D. J.; Scopes D. I.; Pollard F. C.; Page M. J.; Bennett J. M.; Hircock M. L.; McKenzie E. A.; Bhaman M.; Felix R.; Stubberfield C. R.; Turner P. R. Furanyl-1, 3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg. Med. Chem. Lett. 2005, 15(9), 2295-2299.
99. He X.; Brenchley P. E.; Jayson G. C.; Hampson L.; Davies J.; Hampson I. N. Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies. Cancer Res. 2004, 64(11), 3928-3933.
100. Fu J.; Zhao B.; Dong Z.; Sun Y.; Luan H.; Shen X.; Gao X.; Gong F.; Li S.; Song H. Heparanase DNA vaccine delivered by electroporation induces humoral immunity and cytoimmunity in animal models. Vaccine 2012, 30(12), 2187-2196.
101. Zhang J.; Yang J. M.; Wang H. J., Ru G. Q.; Fan D. M. Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS One 2013, 8(1), e52940.
102. Tang X. D.; Wang G. Z.; Guo J.; Lü M. H.; Li C.; Li N.; Chao Y. L.; Li C. Z.; Wu Y. Y.; Hu C. J.; Fang D. C.; Yang S. M. Multiple antigenic peptides based on H-2K(b)-restricted CTL epitopes from murine heparanase induce a potent antitumor immune response in vivo. Mol. Cancer Ther. 2012, 11(5), 1183-1192.